HOLON, Israel, March 6,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN), a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced that it
will present data from its differentiated immuno-oncology
preclinical and clinical pipeline, in two poster presentations at
the American Association for Cancer Research (AACR) annual meeting
on April 5-11, 2024, in San Diego, California.
"It is exciting that the progress we have made to potentially
address immunotherapy resistance from diverse angles will be
reflected at AACR this year," said Anat Cohen-Dayag, Ph.D.,
President, and CEO of Compugen. "While PVRIG and TIGIT are novel
targets discovered with our computational discovery platform, more
recently, we have also discovered a unique and differentiated way
to target a known biological pathway, the IL-18 binding protein
pathway."
Eran Ophir, Ph.D., Chief
Scientific Officer at Compugen, added, "At ACCR we will present
data supporting the unique biology of PVRIG suggesting its role in
sensitizing tumors to other immune checkpoints TIGIT and PD-(L)1.
In addition, in a second presentation we will present data
supporting the therapeutic potential of our high affinity,
potential first-in-class, anti-IL-18 binding protein antibody,
COM503, showing its activity is localized to the tumor
microenvironment with the potential advantage of a wider
therapeutic window than systemically delivered cytokines."
Poster details:
Session Date and
Time: Tuesday, April 9,
2024, 9:00 AM - 12:30 PM
PST
Session Category: Immunology
Session Title: Immune Modulation with Cytokines
Poster Title: Unleashing natural IL-18 activity using
an anti-IL-18BP blocker antibody induces potent immune stimulation
and anti-tumor effects
Published Abstract Number: 4072
Session Date and Time: Wednesday, April 10, 2024, 9:00 AM - 12:30 PM PST
Session Category: Clinical Research
Session Title: Immune Checkpoint Inhibitor Therapy
Poster Title: PVRIG is uniquely expressed in tumor
dendritic cells-rich niches on stem-like memory T cells and its
blockade may induce immune infiltration and activation in
non-inflamed tumor
Published Abstract Number: 7533
The abstracts are available on Compugen's website at
www.cgen.com. The data will be published in the online
Proceedings supplement to the AACR journal Cancer
Research prior to the meeting on Friday, March 22,
2024.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, the Company's
therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune
resistance, of which the most advanced program, COM503, is in IND
enabling studies is licenced to Gilead. COM503 is a potential
first-in-class, high affinity antibody which blocks the interaction
between IL-18 binding protein and IL-18, thereby freeing natural
IL-18 in the tumor microenvironment to inhibit cancer growth.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended, and the safe-harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on the current beliefs,
expectations, and assumptions of Compugen. Forward-looking
statements can be identified using terminology such as "will,"
"may," "expects," "anticipates," "believes," "potential," "plan,"
"goal," "estimate," "likely," "should," "confident," and "intends,"
and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements include, but are not limited to, statements relating to
our expectation to present data from our differentiated
immuno-oncology preclinical and clinical pipeline, in two poster
presentations at the AACR annual meeting in 2024. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance, or
achievements of Compugen to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Among these risks: Compugen's business
model is substantially dependent on entering into collaboration
agreements with third parties and Compugen may not be successful in
generating adequate revenues or commercializing aspects of its
business model; Compugen's approach to the discovery of therapeutic
products is based on its proprietary computational target discovery
infrastructure, which is unproven clinically; Compugen does not
know whether it will be able to discover and develop additional
potential product candidates or products of commercial value; and
the general market, political and economic conditions in the
countries in which Compugen operates, including Israel; and the effect of the evolving nature
of the recent war in Gaza between
Israel and Hamas. These risks and
other risks are more fully discussed in the "Risk Factors" section
of Compugen's most recent Annual Report on Form 20-F as filed with
the Securities and Exchange Commission (SEC) as well as other
documents that may be subsequently filed by Compugen from time to
time with the SEC. In addition, any forward-looking statements
represent Compugen's views only as of the date of this release and
should not be relied upon as representing its views as of any
subsequent date. Compugen does not assume any obligation to update
any forward-looking statements unless required by law.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-data-reflecting-its-diversified-immuno-oncology-pipeline-at-aacr-2024-302081057.html
SOURCE Compugen Ltd.